1. FLT3L and granulocyte macrophage colony-stimulating factor enhance the anti-tumor and immune effects of an HPV16 E6/E7 vaccine
- Author
-
Zhenzhen Ding, Rongying Ou, Liang Zhao, Laiming Mo, Xiangyun Li, Hua Zhu, Yunsheng Xu, Yi Ren, Rui Xu, and Tian Li
- Subjects
Aging ,Papillomavirus E7 Proteins ,HPV16 vaccine ,Lymphocyte ,Uterine Cervical Neoplasms ,Spleen ,Granulocyte ,Cancer Vaccines ,Mice ,Adjuvants, Immunologic ,In vivo ,medicine ,Animals ,Macrophage ,Cytotoxic T cell ,Papillomavirus Vaccines ,Human papillomavirus 16 ,biology ,business.industry ,Granulocyte-Macrophage Colony-Stimulating Factor ,Membrane Proteins ,GM-CSF ,Oncogene Proteins, Viral ,Cell Biology ,Mice, Inbred C57BL ,Repressor Proteins ,FLT3L ,medicine.anatomical_structure ,Granulocyte macrophage colony-stimulating factor ,biology.protein ,Cancer research ,Female ,Antibody ,business ,Research Paper ,medicine.drug - Abstract
HPV16 infections promote the development and progression of cervical cancer. We investigated Fms-like Tyrosine Kinase 3 Ligand and granulocyte macrophage colony-stimulating factor as new adjuvants to an HPV16 vaccine. C57BL/6 mice were immunized by intramuscular injections of HPV16 E6/E7 plasmids every two weeks, three times in all. An in vivo imaging system was used to observe tumor growth and metastasis. Pathological changes to the heart, liver, spleen, lungs, brain and kidneys were recorded, and the survival rate of the mice was determined. The constructed HPV16 E6/E7 vaccine had no notable side effects in terms of physiological or biochemical indexes. Fms-like Tyrosine Kinase 3 Ligand and granulocyte macrophage colony-stimulating factor increased the inhibitory effects of the HPV16 E6/E7 vaccine on tumor growth and metastasis in vivo. The HPV16 E6/E7 vaccine enhanced the survival of mice and increased their serum-specific antibody and interferon-γ levels. Fms-like Tyrosine Kinase 3 Ligand and granulocyte macrophage colony-stimulating factor augmented these effects. In a cytotoxic lymphocyte killing test, Fms-like Tyrosine Kinase 3 Ligand and granulocyte macrophage colony-stimulating factor improved the ability of splenic lymphocytes from HPV16 E6/E7-vaccinated mice to kill B16 cells. As Fms-like Tyrosine Kinase 3 Ligand and granulocyte macrophage colony-stimulating factor enhanced the anti-tumor and immune effects of the HPV16 vaccine, these adjuvants should be considered for the treatment of cervical cancer.
- Published
- 2019